How many Ribociclib clinical trials are there?

159 Ribociclib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 55 are actively recruiting participants. 41 are marked completed.

Are Ribociclib clinical trials recruiting in 2026?

Yes — 55 Ribociclib trials are actively recruiting in 2026, with 582 U.S. sites across 48 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Ribociclib being studied for?

Ribociclib is being studied for Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, HER2-negative Breast Cancer, Breast Neoplasms and 329 more. The trials are grouped by indication on this page.

What phase is Ribociclib in?

Ribociclib clinical trials span 6 Phase 4, 30 Phase 3, 43 Phase 2, 37 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Ribociclib clinical trials?

The lead sponsor across the most Ribociclib trials is Novartis Pharmaceuticals, with 93 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Ribociclib Clinical Trials (2026): 159 Studies for Breast Cancer & Metastatic Breast Cancer

Creator: Hipa.ai Research
Published: 2026-05-14T21:46:57.588Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

159 Ribociclib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 80 indications (including Breast Cancer & Metastatic Breast Cancer) and 70,214 total planned enrollment. 30 Phase 3 Ribociclib trials and 43 Phase 2, 6 Phase 4 are listed. 59 Ribociclib clinical trials are actively recruiting at 582 U.S. sites across 48 states. Most recent activity: NCT06805812 (Dec 2040).

Where to Participate: All Ribociclib Trial Sites in the U.S. (582 sites across 48 states)

Every actively recruiting Ribociclibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Central Alabama Research	Birmingham35209	NCT05827081	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT05467891	Map
AL	Southern Cancer Center	Daphne36526	NCT06065748	Map
AL	Dothan Hematology and Oncology	Dothan36303	NCT05563220	Map
AK	Alaska Oncology and Hematology LLC	Anchorage99508	NCT05827081	Map
AK	Alaska Oncology and Hematology, Llc	Anchorage99508-2974	NCT07492641	Map
AZ	Ironwood Cancer & Research Centers	Chandler85224	NCT06377852	Map
AZ	Banner MD Anderson Cancer Center	Gilbert85234	NCT05508906	Map
AZ	Ironwood Cancer & Research Centers	Gilbert85297	NCT06377852	Map
AZ	Research Site	Gilbert85234	NCT06380751	Map
AZ	Ironwood Cancer & Research Centers	Glendale85306	NCT06377852	Map
AZ	Ironwood Cancer & Research Centers	Goodyear85395	NCT06377852	Map
AZ	Western Reg MC-COH Phoenix	Goodyear85338	NCT05827081	Map
AZ	Ironwood Cancer & Research Centers	Mesa85202	NCT06377852	Map
AZ	Ironwood Cancer & Research Centers	Mesa85206	NCT06377852	Map
AZ	Ironwood Cancer & Research Centers	Phoenix85028	NCT06377852	Map
AZ	Mayo Clinic - Arizona	Phoenix85054	NCT05563220	Map
AZ	St. Joseph's Hospital and Medical Center	Phoenix85004	NCT05203172	Map
AZ	St. Joseph's Hospital and Medical Center	Phoenix85013	NCT05203172	Map
AZ	University of Arizona	Phoenix85004	NCT05467891	Map
AZ	Ironwood Cancer & Research Centers	Scottsdale85260	NCT06377852	Map
AZ	Research Site	Tucson85719	NCT04862663	Map
AZ	The University of Arizona Cancer Center	Tucson85724	NCT05216432	Map
AR	CARTI Cancer Center	Little Rock72205	NCT05827081	Map
AR	Highlands Oncology Group	Springdale72762	NCT05563220	Map
AR	Highlands Oncology Group	Springdale72762	NCT07174336	Map
CA	Beverly Hills Cancer Center	Beverly Hills90211	NCT05827081	Map
CA	Onco Inst of Hope and Innovation	Cerritos90703	NCT05827081	Map
CA	City of Hope	Duarte91010	NCT04802759	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06625775	Map
CA	City of Hope Medical Center	Duarte91010	NCT05238922	Map
CA	City of Hope National Medical	Duarte91010	NCT05827081	Map
CA	California Cancer Associates for Research and Excellence	Encinitas92024	NCT06239467	Map
CA	Research Site	Fountain Valley92708	NCT04862663	Map
CA	Research Site	Fountain Valley92708	NCT06380751	Map
CA	Providence Medical Foundation	Fullerton92835	NCT05827081	Map
CA	Providence Medical Foundation	Fullerton92835	NCT06757634	Map
CA	La Hematology Oncology Medical Group	Glendale91260	NCT06065748	Map
CA	Research Site	Glendale91204	NCT04862663	Map
CA	Research Site	Glendale91206	NCT06380751	Map
CA	Marin Cancer Care	Greenbrae94904	NCT07174336	Map
CA	Marin Cancer Care Inc	Greenbrae94904	NCT06065748	Map
CA	Kaiser Permanente - Harbor City	Harbor City90710	NCT06065748	Map
CA	City of Hope - Orange County Lennar Foundation Cancer Center	Irvine92618-2377	NCT04802759	Map
CA	City of Hope-Lennar Foundation Cancer Center	Irvine92618	NCT05238922	Map
CA	University of California San Diego UCSD	La Jolla92093	NCT06239467	Map
CA	OPN Healthcare (Los Alamitos Location)	Los Alamitos90720	NCT05563220	Map
CA	Cedars Sinai	Los Angeles90048	NCT05563220	Map
CA	Ellison Clinic at Saint John's	Los Angeles90064	NCT05768139	Map
CA	Research Site	Los Angeles90033	NCT04862663	Map
CA	Research Site	Los Angeles90089	NCT06380751	Map
CA	UCLA Hematology Oncology Santa Monica	Los Angeles90404	NCT06757634	Map
CA	UCLA Jonsson Comprehensive Cancer Center	Los Angeles90024	NCT06239467	Map
CA	UCLA UCLA Hem/Onc - Clinical Research Unit	Los Angeles90095	NCT05563220	Map
CA	University of California LA	Los Angeles90095	NCT06726148	Map
CA	University of California Los Angeles	Los Angeles90095	NCT06625775	Map
CA	USC Norris Comprehensive Cancer Center	Los Angeles90033	NCT06065748	Map
CA	Valkyrie Clinical Trials	Los Angeles90067	NCT05238922	Map
CA	Palo Alto Medical Foundation	Mountain View94040	NCT05827081	Map
CA	Research Site	Napa94558	NCT04862663	Map
CA	Hoag - Huntington Beach	Newport Beach92663	NCT06239467	Map
CA	Hoag Memorial Hospital Presbyterian	Newport Beach92663	NCT05870579	Map
CA	Research Site	Newport Beach92663	NCT06380751	Map
CA	USC Norris Cancer Center	Newport Beach92663	NCT06065748	Map
CA	Community Clinical Trials	Orange92868	NCT07054190	Map
CA	UC Irvine Medical Center	Orange92868	NCT05827081	Map
CA	School Of Medicine	Sacramento95817	NCT05827081	Map
CA	Sutter Inst Medical Research	Sacramento95816-5199	NCT05827081	Map
CA	University of California San Diego Moores Cancer Center	San Diego92037	NCT06625775	Map
CA	University of California-San Diego	San Diego90293	NCT05216432	Map
CA	Research Site	San Francisco94158	NCT04862663	Map
CA	UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco94158	NCT05563220	Map
CA	UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco94158	NCT06625775	Map
CA	UCSF Medical Center at Mission Bay	San Francisco94143	NCT05768139	Map
CA	University of California San Francisco Health	San Francisco94158	NCT05508906	Map
CA	University of California, San Francisco (UCSF)	San Francisco94143	NCT04802759	Map
CA	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Santa Monica90404	NCT04802759	Map
CA	Providence Medical Foundation	Santa Rosa95403	NCT07174336	Map
CA	Research Site	Santa Rosa92805	NCT04862663	Map
CA	Stanford Cancer Institute (SCI)	Stanford94305	NCT04802759	Map
CA	The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente	Torrance90502	NCT06065748	Map
CO	Regents of the University of Colorado	Aurora80045	NCT06239467	Map
CO	Research Site	Aurora80045	NCT04862663	Map
CO	Research Site	Aurora80045	NCT06380751	Map
CO	University of Colorado Anschutz Medical Campus	Aurora80045	NCT06377852	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT05508906	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT05768139	Map
CO	Clinical Trial Site	Denver80220	NCT07085767	Map
CO	HealthONE	Denver80218	NCT05216432	Map
CO	Rocky Mountain Cancer Centers	Denver80218	NCT05827081	Map
CO	Sarah Cannon Research Institute at HealthONE	Denver80218	NCT06239467	Map
CO	UCHealth Cherry Creek Medical Center	Denver80206	NCT06377852	Map
CO	UCHealth Highlands Ranch Hospital	Highlands Ranch80129	NCT06377852	Map
CO	Rocky Mountain Cancer Centers	Littleton80120-4413	NCT06065748	Map
CO	Rocky Mountain Cancer Centers	Lone Tree80124	NCT05563220	Map
CO	Rocky Mountain Cancer Centers-Sky Ridge	Lone Tree80124	NCT05238922	Map
CT	Smilow Cancer Hospital Care Center - Derby	Derby06418	NCT06377852	Map
CT	Smilow Cancer Hospital Care Center - Fairfield	Fairfield06824	NCT06377852	Map
CT	Smilow Cancer Hospital at Glastonbury	Glastonbury06033	NCT06377852	Map
CT	Smilow Cancer Hospital Care Center - Greenwich	Greenwich06830	NCT06377852	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT06377852	Map
CT	Smilow Cancer Hospital at Saint Francis	Hartford06105	NCT06377852	Map
CT	Research Site	New Haven06510	NCT04862663	Map
CT	Smilow Cancer Hospital - Yale New Haven Health	New Haven06510	NCT06377852	Map
CT	Yale Cancer Center	New Haven06520	NCT05867251	Map
CT	Yale University	New Haven06510	NCT05216432	Map
CT	Yale University	New Haven06511	NCT06953882	Map
CT	Yale University/Yale Cancer Center/Yale School of Medicine	New Haven06510	NCT06377852	Map
CT	Smilow Cancer Hospital Care Center - North Haven	North Haven06473	NCT06377852	Map
CT	Smilow Cancer Hospital Care Center - Torrington	Torrington06790	NCT06377852	Map
CT	Smilow Cancer Hospital Care Center - Trumbull	Trumbull06611	NCT06377852	Map
CT	Smilow Cancer Hospital Care Center - Waterbury	Waterbury06708	NCT06377852	Map
CT	Smilow Cancer Hospital - Waterford	Waterford06385	NCT06377852	Map
DE	Research Site	Newark19713	NCT04862663	Map
DC	Children's National Medical Center	Washington D.C.20010	NCT05843253	Map
DC	George Washington Cancer Center	Washington D.C.20037	NCT05563220	Map
DC	Georgetown University Lombardi Cancer Center	Washington D.C.20007-2197	NCT05827081	Map
DC	Georgetown University Medical Center	Washington D.C.20007	NCT06065748	Map
DC	MedStar Washington Hosp Center	Washington D.C.20010	NCT06065748	Map
DC	Washington Hospital Center	Washington D.C.20010	NCT05827081	Map
FL	Advent Health (Florida Hospital) - Altamonte Springs	Altamonte Springs32701	NCT05563220	Map
FL	AdventHealth Altamonte	Altamonte Springs32701	NCT06065748	Map
FL	AdventHealth Altamonte Springs	Altamonte Springs32701	NCT05827081	Map
FL	Clermont Oncology Center	Clermont34711	NCT07174336	Map
FL	Holy Cross Health	Fort Lauderdale33308	NCT05827081	Map
FL	Florida Cancer Specialists	Fort Myers33901	NCT06726148	Map
FL	Florida Cancer Specialists - Broadway	Fort Myers33901	NCT06065748	Map
FL	Hialeah Hospital	Hialeah33013	NCT05827081	Map
FL	Memorial Cancer Institute	Hollywood33021	NCT05827081	Map
FL	Research Site	Hollywood33021	NCT06380751	Map
FL	Cancer Specialists of North Florida	Jacksonville32256	NCT06065748	Map
FL	Mayo Clinic - Jacksonville	Jacksonville32224	NCT05563220	Map
FL	Research Site	Jacksonville32224	NCT06380751	Map
FL	Jupiter Medical Center	Jupiter33458	NCT05827081	Map
FL	Miami Cancer Institute	Miami33176	NCT06377852	Map
FL	Mount Sinai Medical Center Comprehensive Cancer Center	Miami Beach33140	NCT05238922	Map
FL	Ocala Research Institute, Inc	Ocala34474	NCT05827081	Map
FL	Mid Florida Hematology and Oncology Center	Orange City32763	NCT07174336	Map
FL	Advent Health Hematology and Oncology	Orlando32804	NCT05508906	Map
FL	Florida Cancer Specialists	Orlando32827	NCT05216432	Map
FL	BRCR Medical Center, Inc- Internal Medicine	Plantation33322	NCT06757634	Map
FL	Miami Cancer Institute	Plantation33324	NCT06377852	Map
FL	Florida Cancer Specialists	Sarasota34232	NCT05867251	Map
FL	Comprehensive Hematology Oncology	St. Petersburg33709	NCT06065748	Map
FL	Florida Cancer Specialists - North;725 6th Ave South (St. Petersburg)	St. Petersburg33701-4553	NCT06065748	Map
FL	BRCR Medical Center, INC	Tamarac33321	NCT06757634	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05768139	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05867251	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06409390	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06625775	Map
FL	Florida Cancer Specialists - EAST - SCRI - PPDS	West Palm Beach33401-3406	NCT06065748	Map
GA	University Cancer and Blood Center LLC	Athens30607	NCT05827081	Map
GA	Emory University Hospital	Atlanta30322	NCT05203172	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT05203172	Map
GA	Emory University Winship Cancer Institute	Atlanta30322	NCT06377852	Map
GA	Grady Health System	Atlanta30303	NCT06065748	Map
GA	Investigational Drug Service Emory University Clinic	Atlanta30322	NCT05203172	Map
GA	Winship Cancer Institute of Emory University	Atlanta30322	NCT05203172	Map
GA	Winship Cancer Institute of Emory University	Atlanta30329	NCT06065748	Map
GA	Winship Cancer Institute, Emory University	Atlanta30322	NCT05768139	Map
GA	Lewis Cancer and Research Pavilion	Savannah31405	NCT06377852	Map
GA	Summit Cancer Care PC	Savannah31405	NCT05827081	Map
GA	Summit Cancer Care, PC	Savannah31405	NCT07174336	Map
HI	Hawaii Cancer Care	Honolulu96813	NCT05827081	Map
IL	Illinois CancerCare-Bloomington	Bloomington61704	NCT07391774	Map
IL	Illinois CancerCare-Canton	Canton61520	NCT07391774	Map
IL	SIH Cancer Institute	Carterville62918	NCT07391774	Map
IL	Illinois CancerCare-Carthage	Carthage62321	NCT07391774	Map
IL	Affiliated Oncologists IL	Chicago60415	NCT05827081	Map
IL	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago60611	NCT05843253	Map
IL	Northwestern Feinberg Scholl of Medicine Prentice Women's Hospital	Chicago60611	NCT05563220	Map
IL	Northwestern Memorial Hospital	Chicago60611	NCT05683418	Map
IL	Northwestern University	Chicago60611	NCT06062498	Map
IL	Research Site	Chicago60611	NCT06380751	Map
IL	University of Chicago Medical Center	Chicago60637	NCT05216432	Map
IL	University of Illinois Cancer Center	Chicago60612	NCT05467891	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT07391774	Map
IL	Decatur Memorial Hospital	Decatur62526	NCT07391774	Map
IL	Illinois CancerCare-Eureka	Eureka61530	NCT07391774	Map
IL	Research Site	Evanston60201	NCT06380751	Map
IL	Illinois CancerCare-Galesburg	Galesburg61401	NCT07391774	Map
IL	Hope And Healing Care	Hinsdale60521	NCT05827081	Map
IL	Illinois CancerCare-Kewanee Clinic	Kewanee61443	NCT07391774	Map
IL	Illinois CancerCare-Macomb	Macomb61455	NCT07391774	Map
IL	Cancer Care Specialists For Illinois	O'Fallon62269	NCT07492641	Map
IL	Illinois CancerCare-Ottawa Clinic	Ottawa61350	NCT07391774	Map
IL	Advocate Lutheran General Hospital	Park Ridge60068	NCT06065748	Map
IL	Illinois CancerCare-Pekin	Pekin61554	NCT07391774	Map
IL	Clinical Trial Site	Peoria61615	NCT07085767	Map
IL	Illinois CancerCare-Peoria	Peoria61615	NCT07391774	Map
IL	Illinois CancerCare-Peru	Peru61354	NCT07391774	Map
IL	Illinois CancerCare-Princeton	Princeton61356	NCT07391774	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT07391774	Map
IL	Springfield Clinic	Springfield62702	NCT06065748	Map
IL	Research Site	Urbana61801	NCT06380751	Map
IL	Illinois CancerCare - Washington	Washington61571	NCT07391774	Map
IL	Research Site	Winfield60190	NCT06380751	Map
IL	Midwestern Reg MC COH Chicago	Zion60099	NCT05827081	Map
IN	Parkview Research Center	Fort Wayne46845	NCT05467891	Map
IN	Community Health Network	Indianapolis46250	NCT05216432	Map
IN	Indiana University Health University Hospital	Indianapolis46202	NCT07174336	Map
IN	Indiana University Simon Comprehensive Cancer Center	Indianapolis46202	NCT06625775	Map
IN	Investigative Clinical R of Indiana	Indianapolis46260	NCT05827081	Map
IA	Mission Cancer + Blood - IMMC	Des Moines50309	NCT06065748	Map
IA	University of Iowa	Iowa City52242	NCT05508906	Map
IA	University of Iowa	Iowa City52242	NCT05768139	Map
IA	University of Iowa Hospitals and Clinics	Iowa City52242	NCT05467891	Map
IA	University of Iowa Health Care	Waukee50263	NCT05827081	Map
KS	MD Alliance for Multispecialty Research, LLC	Merriam66204	NCT05563220	Map
KS	The University of Kansas Cancer Center	Westwood66205	NCT06377852	Map
KS	The University of Kansas Cancer Center	Westwood66205	NCT06757634	Map
KS	University of Kansas Cancer Center	Westwood66205	NCT05827081	Map
KS	University of Kansas Medical Center	Westwood66205	NCT05870579	Map
KS	Cancer Center of Kansas	Wichita67214-3728	NCT05827081	Map
KY	Baptist Health Hamburg	Lexington40509	NCT06065748	Map
KY	Baptist Health Lexington	Lexington40503	NCT06065748	Map
KY	Baptist Health Louisville	Louisville40207	NCT06065748	Map
KY	Research Site	Louisville40202	NCT04862663	Map
KY	Mercy Health-Paducah Cancer Center	Paducah42003	NCT06757634	Map
LA	Louisiana State University Health Sciences Center	New Orleans70112	NCT05768139	Map
LA	Willis-Knighton Cancer Center	Shreveport71103	NCT05827081	Map
ME	The Jackson Laboratory (JAX) - Harold Alfond Center for Cancer Care	Augusta04330	NCT06377852	Map
ME	The Jackson Laboratory (JAX) - Northern Light Cancer Care	Brewer04412	NCT06377852	Map
ME	Clinical Trial Site	Scarborough04074	NCT07085767	Map
ME	New England Cancer Specialists	Scarborough04074	NCT06065748	Map
MD	Maryland Oncology Hematology	Annapolis21401	NCT06065748	Map
MD	Research Site	Annapolis21401	NCT04862663	Map
MD	Johns Hopkins School of Medicine	Baltimore21287	NCT05563220	Map
MD	Mercy Medical Center	Baltimore21202	NCT05827081	Map
MD	American Oncology Partners, P.A.	Bethesda20817	NCT06757634	Map
MD	Maryland Oncology Hematology P A	Silver Spring20904	NCT05827081	Map
MD	Research Site	Silver Spring20902	NCT06380751	Map
MD	Research Site	Silver Spring20904	NCT06380751	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT05683418	Map
MA	Boston Medical Center	Boston02118	NCT05827081	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT05508906	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT05563220	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT05827081	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06065748	Map
MA	Dana Farber Cancer Institute	Boston02115	NCT06726148	Map
MA	Dana-Farber Cancer Insitute	Boston02215	NCT06625775	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05216432	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05683418	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05768139	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06377852	Map
MA	Massachusetts General Hospital	Boston02114	NCT05203172	Map
MA	Massachusetts General Hospital	Boston02114	NCT05216432	Map
MA	Massachusetts General Hospital	Boston02114	NCT05563220	Map
MA	Massachusetts General Hospital	Boston02114	NCT04802759	Map
MA	Massachusetts General Hospital	Boston02115	NCT05768139	Map
MA	Massachusetts General Hospital	Boston02114	NCT06239467	Map
MA	Massachusetts General Hospital	Boston02114	NCT06625775	Map
MA	Research Site	Boston02215	NCT06380751	Map
MA	Tufts Medical Center	Boston02111	NCT05467891	Map
MA	Dana-Farber Brigham Cancer Center Foxborough	Foxborough02035	NCT06377852	Map
MA	Dana-Farber Cancer Institute Merrimack Valley	Methuen01844	NCT06377852	Map
MA	Dana Farber Brigham Women Cancer	Milford01757	NCT05827081	Map
MA	Dana-Farber Brigham Cancer Center at Milford Regional Medical Center	Milford01757	NCT06377852	Map
MA	Dana-Farber Brigham Cancer Center at South Shore Health	Weymouth02190	NCT06377852	Map
MI	C.S. Mott Children's Hospital	Ann Arbor48109	NCT05843253	Map
MI	University of Michigan	Ann Arbor48109	NCT05216432	Map
MI	University of Michigan	Ann Arbor48109	NCT05996107	Map
MI	University of Michigan Health System	Ann Arbor48109	NCT05467891	Map
MI	Barbara Ann Karmanos Cancer Institute	Detroit48201	NCT05563220	Map
MI	Henry Ford Health	Detroit48126	NCT05508906	Map
MI	Henry Ford Health System	Detroit48202	NCT06757634	Map
MI	Henry Ford Hospital	Detroit48202	NCT06065748	Map
MI	Research Site	Detroit48236	NCT04862663	Map
MI	Research Site	Detroit48202	NCT06380751	Map
MI	Research Site	Grand Rapids49503	NCT04862663	Map
MI	START Midwest	Grand Rapids49546	NCT05768139	Map
MI	Research Site	Royal Oak48073	NCT06380751	Map
MI	University of Michigan Health West	Wyoming49519	NCT05996107	Map
MN	Avera Cancer Institute - Marshall	Marshall56258	NCT07405801	Map
MN	Allina Hlth Cancer Inst Minneapolis	Minneapolis55407	NCT05827081	Map
MN	Clinical Trial Site	Minneapolis55404	NCT07085767	Map
MN	Minnesota Oncology Hematology P A	Minneapolis55404	NCT05827081	Map
MN	Regents of the University of Minnesota	Minneapolis55455	NCT05508906	Map
MN	Mayo Clinic - Rochester	Rochester55905	NCT05563220	Map
MN	Research Site	Rochester55905	NCT06380751	Map
MN	HealthPartners Cancer Research Center	Saint Paul55101	NCT05203172	Map
MN	Regions Hospital Pharmacy	Saint Paul55101	NCT05203172	Map
MS	Jackson Oncology Associates	Jackson39202	NCT05827081	Map
MO	Research Site	Hannibal63401	NCT04862663	Map
MO	Clinical Trial Site	Kansas City64132	NCT07085767	Map
MO	HCA Midwest Division	Kansas City64132	NCT05827081	Map
MO	HCA Midwest Division	Kansas City64132	NCT06065748	Map
MO	Saint Luke's Cancer Institute	Kansas City64111-3220	NCT05768139	Map
MO	Saint Luke's Cancer Institute	Kansas City64111-5965	NCT06757634	Map
MO	St. Lukes Hospital of Kansas City	Kansas City64111	NCT06625775	Map
MO	Cancer Care Center of O'Fallon	O'Fallon62269	NCT06065748	Map
MO	Research Site	Springfield65804	NCT06380751	Map
MO	Barnes-Jewish Hospital	St Louis63110	NCT05203172	Map
MO	Research Site	St Louis63110	NCT04862663	Map
MO	Research Site	St Louis63141	NCT06188520	Map
MO	Siteman Cancer Center	St Louis63108	NCT05203172	Map
MO	WA Uni School Of Med	St Louis63110	NCT05827081	Map
MO	WA Uni School Of Med	St Louis63110	NCT06726148	Map
MO	Washington University	St Louis63110	NCT05203172	Map
MO	Washington University	St Louis63110	NCT05768139	Map
MO	Washington University School of Medicine	St Louis63110	NCT05203172	Map
MO	Washington University School of Medicine	St Louis63110	NCT06625775	Map
MO	Washington University School of Medicine in Saint Louis	St Louis63110	NCT06757634	Map
MO	Washington University School of Medicine in St. Louis	St Louis63110	NCT05563220	Map
MO	Washington University School of Medicine St. Louis	St Louis63110	NCT05216432	Map
MO	Washington University, School of Medicine	St Louis63110	NCT05508906	Map
MT	Intermountain Healthcare	Billings59102	NCT05827081	Map
MT	SCL Health - Cancer Centers of Montana	Billings59102	NCT06757634	Map
NE	Oncology Hematology West - Grand Island	Grand Island68803	NCT06065748	Map
NE	Nebraska Cancer Specialists	Omaha68154	NCT05827081	Map
NE	Nebraska Cancer Specialists	Omaha68130-2042	NCT07492641	Map
NE	Oncology Hematology West - Legacy	Omaha68130-2042	NCT06065748	Map
NE	Research Site	Omaha68130	NCT04862663	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT05467891	Map
NV	Comprehensive Cancer Centers of Nevada	Las Vegas89169	NCT05683418	Map
NV	Comprehensive Cancer Centers of Nevada	Las Vegas89169	NCT06239467	Map
NV	Cancer Care Specialists	Reno89511	NCT05827081	Map
NV	Renown Regional Medical Center	Reno89502	NCT05216432	Map
NV	Renown Regional Medical Center	Reno89502	NCT05827081	Map
NH	Dana-Farber/New Hampshire Oncology-Hematology	Londonderry03053	NCT06377852	Map
NJ	Research Site	Camden08103	NCT04862663	Map
NJ	Research Site	Camden08103	NCT06380751	Map
NJ	Jefferson Health - Cherry Hill	Cherry Hill08002	NCT07174336	Map
NJ	Astera Cancer Care	East Brunswick08816	NCT05563220	Map
NJ	Astera Cancer Care East Brunswick	East Brunswick08816	NCT06065748	Map
NJ	Astera Cancer Care East Brunswick	East Brunswick08816-4096	NCT07492641	Map
NJ	Summit Health	Florham Park07932	NCT05827081	Map
NJ	Summit Medical Group	Florham Park07932	NCT05563220	Map
NJ	Cooperman Barnabas Medical Center	New Brunswick08901	NCT05563220	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT05467891	Map
NJ	Rutgers University	New Brunswick08901	NCT05216432	Map
NJ	Penn Medicine - Princeton Health	Plainsboro08536	NCT06377852	Map
NJ	The Valley Hospital	Ridgewood07450	NCT05827081	Map
NJ	Sidney Kimmel Cancer Center - Washington Township	Sewell08080	NCT07174336	Map
NM	Lovelace Medical Center - Saint Joseph Square	Albuquerque87102	NCT06377852	Map
NM	Lovelace Women's Hospital	Albuquerque87109	NCT06377852	Map
NM	Presbyterian Kaseman Hospital	Albuquerque87110	NCT06377852	Map
NM	Presbyterian Medical Group	Albuquerque87110	NCT05827081	Map
NM	The University of New Mexico Comprehensive Cancer Center	Albuquerque87131	NCT06377852	Map
NM	University of New Mexico Comprehensive Cancer Center	Albuquerque87102	NCT05467891	Map
NM	Memorial Medical Center	Las Cruces88011	NCT06377852	Map
NM	Presbyterian Rust Medical Center/Jorgensen Cancer Center	Rio Rancho87124	NCT06377852	Map
NM	Clinical Trial Site	Santa Fe87505	NCT07085767	Map
NY	Queens Cancer Center of Queens Hospital	Jamaica11432	NCT05827081	Map
NY	Queens Hospital Cancer Center	Jamaica11432	NCT06065748	Map
NY	Optum Health	Lake Success11042	NCT05827081	Map
NY	Perlmutter Cancer Center at NYU Langone Hospital - Long Island	Mineola11501	NCT05867251	Map
NY	Research Site	Mineola11501	NCT06380751	Map
NY	Columbia University Herbert Irving Comprehensive Cancer Center	New York10032	NCT05216432	Map
NY	Columbia University Irving Medical Center	New York10032	NCT06625775	Map
NY	Ichan School of Medicine at Mount Sinai	New York10029	NCT05508906	Map
NY	Memorial Sloan Kettering	New York10065	NCT05216432	Map
NY	Memorial Sloan Kettering	New York10017	NCT06726148	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05768139	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06625775	Map
NY	Mount Sinai School of Medicine	New York10029	NCT05827081	Map
NY	New York University Clinical Cancer Center	New York10016	NCT05467891	Map
NY	NYU Langone	New York10016	NCT05216432	Map
NY	NYU Langone Health	New York10016	NCT05563220	Map
NY	NYU Langone Medical Center (Tisch Hospital)	New York10016	NCT05867251	Map
NY	Research Site	New York10065	NCT04862663	Map
NY	Research Site	New York10016	NCT06380751	Map
NY	Research Site	New York10065	NCT06380751	Map
NY	Research Site	Stony Brook11790	NCT06380751	Map
NY	Stony Brook University	Stony Brook11794	NCT06239467	Map
NY	Clinical Research Alliance, Inc.	Westbury11590	NCT06757634	Map
NC	Levine Cancer Institute	Albemarle28001	NCT06377852	Map
NC	Atrium Health Levine Cancer Institute	Charlotte28204	NCT05508906	Map
NC	Levine Cancer Institute	Charlotte28204	NCT04802759	Map
NC	Levine Cancer Institute	Charlotte28204	NCT06377852	Map
NC	Levine Cancer Institute	Charlotte28210	NCT06377852	Map
NC	Levine Cancer Institute	Charlotte28211	NCT06377852	Map
NC	Levine Cancer Institute	Charlotte28262	NCT06377852	Map
NC	Levine Cancer Institute	Charlotte28277	NCT06377852	Map
NC	Levine Cancer Institute	Concord28025	NCT06377852	Map
NC	Duke Cancer Center	Durham27710	NCT05203172	Map
NC	Duke Cancer Network	Durham27710	NCT05827081	Map
NC	Duke University Health System	Durham27708	NCT05843253	Map
NC	Investigational Chemotherapy Service	Durham27710	NCT05203172	Map
NC	Levine Cancer Institute	Forest City28043	NCT06377852	Map
NC	Levine Cancer Institute	Gastonia28054	NCT06377852	Map
NC	Cone Health Cancer Center	Greensboro27403	NCT05827081	Map
NC	Levine Cancer Institute	Huntersville28078	NCT06377852	Map
NC	Levine Cancer Institute	Lincolnton28092	NCT06377852	Map
NC	Levine Cancer Institute	Matthews28104	NCT06377852	Map
NC	Levine Cancer Institute	Monroe28112	NCT06377852	Map
NC	Duke Women Cancer Care	Raleigh27607	NCT06065748	Map
NC	Levine Cancer Institute	Shelby28150	NCT06377852	Map
ND	Sanford Research USD Fargo	Fargo58122	NCT05827081	Map
OH	Gabrail Cancer Center Research	Canton44718-2566	NCT07492641	Map
OH	Cincinnati Children's Hospital Medical Center	Cincinnati45229	NCT05843253	Map
OH	UH Cleveland Medical Center	Cleveland44106	NCT05768139	Map
OH	UHCMC Seidman Cancer Center	Cleveland44106	NCT05996107	Map
OH	University Hospitals Cleveland Medical Center	Cleveland44106	NCT05867251	Map
OH	Clinical Trial Site	Columbus43219	NCT07085767	Map
OH	Nationwide Children's Hospital	Columbus43235	NCT05843253	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT05467891	Map
OH	Stefanie Spielman Comprehensive Breast Center	Columbus43212	NCT05768139	Map
OH	Stefanie Spielman Comprehensive Breast Center at Olentangy River Road	Columbus43210	NCT06757634	Map
OK	Oklahoma University	Oklahoma City73117	NCT05867251	Map
OR	Good Samaritan Regional Medical Center	Corvallis97330	NCT05827081	Map
OR	Good Samaritan Regional Medical Center	Corvallis97330	NCT07174336	Map
OR	Oncology Associates of Oregon	Eugene97401	NCT07174336	Map
OR	Oncology Associates of Oregon PC	Eugene97401-8122	NCT05827081	Map
OR	Research Site	Gresham97030	NCT04862663	Map
OR	Asante Rogue Regional Medical Center	Medford97504-8332	NCT06065748	Map
OR	Northwest Cancer Specialists	Portland97210	NCT05827081	Map
OR	Providence Cancer Institute	Portland97213	NCT05867251	Map
OR	Providence Cancer Institute Franz Clinic	Portland97213	NCT05768139	Map
OR	Providence Portland Medical Center	Portland97213	NCT05467891	Map
OR	Oregon Oncology Specialists Salem	Salem97301	NCT05827081	Map
PA	Alliance Cancer Specialists	Bensalem19020	NCT06065748	Map
PA	Consultants In Med Onco And Hema	Drexel Hill19026	NCT05827081	Map
PA	Univ of Pittsburg Med Ctr Pinnacle	Harrisburg17109	NCT05827081	Map
PA	Penn State Cancer Institute	Hershey17033	NCT05467891	Map
PA	Research Site	Hershey17033	NCT06380751	Map
PA	Ann B. Barshinger Cancer Institute	Lancaster17604	NCT06065748	Map
PA	Penn Medicine - Lancaster General Hospital	Lancaster17601	NCT06377852	Map
PA	Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit	Philadelphia19106	NCT06065748	Map
PA	ECOG-ACRIN Cancer Research Group	Philadelphia19103	NCT07391774	Map
PA	Jefferson Hospital Northeast	Philadelphia19114	NCT07174336	Map
PA	Penn Medicine - Pennsylvania Hospital	Philadelphia19106	NCT06377852	Map
PA	Penn Medicine - Perelman Center for Advanced Medicine	Philadelphia19104	NCT06377852	Map
PA	Research Site	Philadelphia19104	NCT06380751	Map
PA	Rittenhouse Hematology/Oncology	Philadelphia19004	NCT06757634	Map
PA	Sidney Kimmel Cancer Center (SKCC) at Jefferson Health	Philadelphia19107	NCT05867251	Map
PA	Thomas Jefferson University - Clinical Research Institute	Philadelphia19107	NCT07174336	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT04802759	Map
PA	University of Pennsylvania	Philadelphia19106	NCT05683418	Map
PA	University of Pennsylvania Abramson Cancer Center	Philadelphia19104	NCT05238922	Map
PA	Research Site	Pittsburgh15213	NCT04862663	Map
PA	Research Site	Pittsburgh15215	NCT06380751	Map
PA	Clinical Trial Site	Sayre18840	NCT07085767	Map
PA	Penn Medicine - Chester County Hospital	West Chester19380	NCT06377852	Map
PA	Asplundh Cancer Pavilion	Willow Grove19090	NCT07174336	Map
RI	Brown University Health	Providence02905	NCT06065748	Map
RI	Research Site	Providence02903	NCT06188520	Map
RI	Rhode Island Hospital	Providence02903	NCT05827081	Map
RI	W&IH of RI Breast Health Center of Women and Infants Hospital of Rhode Island	Providence02905	NCT05563220	Map
RI	Smilow Cancer Hospital - Westerly	Westerly02891	NCT06377852	Map
SC	St. Joseph's Candler Bluffton Campus	Bluffton29910	NCT06377852	Map
SC	Medical University of South Carolina	Charleston29425	NCT05467891	Map
SC	Medical University of South Carolina	Charleston29425	NCT06065748	Map
SC	Bon Secours St Francis Cancer Center	Greenville29607	NCT05827081	Map
SC	SC Cancer Specialists - Hilton Head at St. Joseph's/Candler	Hilton Head Island29926	NCT06377852	Map
SC	Levine Cancer Institute	Rock Hill29732	NCT06377852	Map
SC	Lexington Medical Center	West Columbia29169	NCT05827081	Map
SC	Regional Medical Oncology NC	Wilson27893	NCT05827081	Map
SD	Avera Cancer Institute - Aberdeen	Aberdeen57401	NCT06065748	Map
SD	Avera Cancer Institute - Aberdeen	Aberdeen57401	NCT07405801	Map
SD	Avera Cancer Institute - Mitchell	Mitchell57301	NCT07405801	Map
SD	Avera Cancer Institute - Pierre, SD	Pierre57501	NCT07405801	Map
SD	Avera Cancer Institute	Sioux Falls57105	NCT06065748	Map
SD	Avera Cancer Institute	Sioux Falls57105	NCT07405801	Map
SD	Sanford USD Medical Center	Sioux Falls57104	NCT05827081	Map
SD	AMG Oncology and Hematology Avera Cancer Institute - Yankton	Yankton57078	NCT07405801	Map
TN	Research Site	Chattanooga37404	NCT04862663	Map
TN	Research Site	Chattanooga37404	NCT06380751	Map
TN	Tennessee Oncology - Chattanooga Oncology & Hematology Associates	Chattanooga37404	NCT03424005	Map
TN	The West Clinic	Germantown38138	NCT03424005	Map
TN	The West Clinic, PLLC dba West Cancer Center	Germantown38138	NCT05768139	Map
TN	West Cancer Center	Germantown38138	NCT04802759	Map
TN	West Cancer Center	Germantown38138	NCT06065748	Map
TN	Baptist Memorial Healthcare	Memphis38120	NCT06377852	Map
TN	Henry-Joyce Cancer Clinic, The Vanderbilt Clinic	Nashville37232	NCT05508906	Map
TN	Research Site	Nashville37203	NCT04862663	Map
TN	Research Site	Nashville37201	NCT06188520	Map
TN	Research Site	Nashville37203	NCT06380751	Map
TN	Sarah Cannon Cancer Center	Nashville37203	NCT05683418	Map
TN	Sarah Cannon Research Institute	Nashville37203	NCT05768139	Map
TN	Sarah Cannon Research Institute	Nashville37203	NCT05827081	Map
TN	Sarah Cannon Research Institute / Tennessee Oncology	Nashville37203	NCT05563220	Map
TN	Sarah Cannon Research Institute SCRI	Nashville37203	NCT07174336	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06065748	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06625775	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06726148	Map
TN	SCRI Oncology Partners - Nashville	Nashville37203	NCT06239467	Map
TN	Tennessee Oncology	Nashville37203	NCT05216432	Map
TN	Tennessee Oncology PLLC	Nashville37203	NCT03424005	Map
TN	Vanderbilt University Medical Center	Nashville37212	NCT03424005	Map
TN	Vanderbilt-Ingram Cancer Center	Nashville37232	NCT05683418	Map
TN	Clinical Trial Site	Tennessee City37203	NCT07085767	Map
TX	Texas Oncology Cancer Center	Austin78731	NCT06065748	Map
TX	World Research Link	Baytown77521	NCT07174336	Map
TX	Research Site	Dallas75246	NCT04862663	Map
TX	SCRI at Mary Crowley	Dallas75230	NCT06625775	Map
TX	Texas Oncology - Baylor Charles A. Sammons Cancer Center	Dallas75246	NCT05563220	Map
TX	Texas Oncology - DFW	Dallas75246	NCT05867251	Map
TX	Texas Oncology-Baylor Charles A. Sammons Cancer Center	Dallas75246-2092	NCT05768139	Map
TX	University of Texas Southwestern Medical Center	Dallas75235	NCT05216432	Map
TX	University of Texas Southwestern Medical Center	Dallas75390	NCT06625775	Map
TX	USO - Texas Oncology	Dallas75246	NCT07174336	Map
TX	UT Southwestern Medical Center	Dallas75390	NCT07174336	Map
TX	Clinical Trial Site	Denton76201	NCT07085767	Map
TX	Clinical Trial Site	El Paso79902	NCT07085767	Map
TX	El Paso Texas Oncology	El Paso79902	NCT05827081	Map
TX	Texas Oncology - West Texas	El Paso79902	NCT07174336	Map
TX	Texas Oncology - Flower Mound	Flower Mound75028	NCT05683418	Map
TX	JPS Oncology & Infusion Center	Fort Worth76104	NCT06065748	Map
TX	Clinical Trial Site	Houston77024	NCT07085767	Map
TX	Kelsey Seybold Clinic	Houston77025	NCT05827081	Map
TX	MD Anderson Cancer Center	Houston77030	NCT05508906	Map
TX	MD Anderson Cancer Center Texas	Houston77030	NCT05563220	Map
TX	MD Anderson Cancer Center Uni of Te	Houston77030	NCT06726148	Map
TX	Oncology Consultants P.A.	Houston77030	NCT07174336	Map
TX	Research Site	Houston77030	NCT04862663	Map
TX	Research Site	Houston77030	NCT06188520	Map
TX	Research Site	Houston77030	NCT06380751	Map
TX	Research Site	Houston77054	NCT06380751	Map
TX	Texas Children's Hospital	Houston77030	NCT05843253	Map
TX	The University of Texas M.D. Anderson Cancer Center	Houston77030	NCT05216432	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT06625775	Map
TX	University of Texas	Houston77030-4099	NCT05827081	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030	NCT05768139	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030-4000	NCT06757634	Map
TX	Texas Oncology - DFW	Irving75063	NCT06065748	Map
TX	Nova Oncology	McAllen78504	NCT07174336	Map
TX	Texas Oncology P A Plano East	Plano75075	NCT05827081	Map
TX	Mays Cancer Center	San Antonio78229	NCT06757634	Map
TX	Research Site	San Antonio78229	NCT04862663	Map
TX	Research Site	San Antonio78240	NCT04862663	Map
TX	Research Site	San Antonio78240	NCT06380751	Map
TX	START San Antonio	San Antonio78229	NCT05768139	Map
TX	Texas Oncology - San Antonio Medical Center	San Antonio78240	NCT07174336	Map
TX	University of Texas San Antonio (UTSA)	San Antonio78229	NCT06625775	Map
TX	UT Health San Antonio	San Antonio78229	NCT05563220	Map
TX	US Oncology Research Network	The Woodlands77380	NCT07174336	Map
TX	Texas Oncology PA Tyler	Tyler75702	NCT05827081	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT04315233	Map
UT	Research Site	Salt Lake City84106	NCT04862663	Map
UT	University of Utah- Huntsman Cancer Center	Salt Lake City84112	NCT05216432	Map
UT	START Mountain Region	West Valley City84119	NCT05768139	Map
VA	University of Virginia Health System	Charlottesville22908	NCT05467891	Map
VA	Inova Schar Cancer Center	Fairfax22031	NCT05216432	Map
VA	Inova Schar Cancer Institute	Fairfax22031	NCT04315233	Map
VA	NEXT Oncology Virginia	Fairfax22031	NCT06239467	Map
VA	NEXT Virginia	Fairfax22301	NCT05216432	Map
VA	NEXT Virginia	Fairfax22031	NCT05867251	Map
VA	Research Site	Fairfax22031	NCT04862663	Map
VA	USO-Virginia Cancer Specialists, PC	Fairfax22031	NCT05768139	Map
VA	Virginia Cancer Institute	Fairfax22031	NCT05238922	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT05563220	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT05683418	Map
VA	Virginia Cancer Specialists, PC	Fairfax22031	NCT06065748	Map
VA	Bon Secours St. Francis Medical Oncology Center	Midlothian23114-3203	NCT06757634	Map
VA	Bon Secours Virginia Health System	Midlothian23114	NCT05827081	Map
VA	Research Site	Midlothian23114	NCT04862663	Map
VA	Research Site	Norfolk23502	NCT04862663	Map
VA	Research Site	Norfolk23502	NCT06380751	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT05563220	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT05827081	Map
VA	Virginia Commonwealth University	Richmond23298	NCT05467891	Map
VA	Virginia Commonwealth University - Massey Cancer Center	Richmond23219	NCT06065748	Map
WA	Northwest Medical Specialties	Bonney Lake98391	NCT06377852	Map
WA	Northwest Medical Specialties	Federal Way98003	NCT06377852	Map
WA	Northwest Medical Specialties	Gig Harbor98332	NCT06377852	Map
WA	Kadlec Clinic Hematology and Onco	Kennewick99336	NCT05827081	Map
WA	Providence Regional Cancer System	Lacey98503	NCT05827081	Map
WA	Northwest Medical Specialties	Olympia98502	NCT06377852	Map
WA	Northwest Medical Specialties	Puyallup98373	NCT06377852	Map
WA	Valley Medical Center Research	Renton98055	NCT05827081	Map
WA	Fred Hutch Cancer Research	Seattle98109	NCT06726148	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06239467	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06625775	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06757634	Map
WA	Seattle Children's Hospital	Seattle98105	NCT05843253	Map
WA	Cancer Care Northwest	Spokane Valley99216	NCT05563220	Map
WA	Northwest Medical Specialties	Tacoma98405	NCT05508906	Map
WA	Northwest Medical Specialties	Tacoma98405	NCT05827081	Map
WA	Northwest Medical Specialties	Tacoma98405	NCT06065748	Map
WA	Northwest Medical Specialties	Tacoma98405	NCT06377852	Map
WA	Northwest Medical Specialties (Nwms) - Puyallup - Medical Oncology (Rainier Hematology-Oncology)/Exigent Research Network; LLC	Tacoma98405	NCT05563220	Map
WA	Research Site	Tacoma98405	NCT04862663	Map
WA	Research Site	Tacoma98405	NCT06380751	Map
WV	Research Site	Morgantown26506	NCT06380751	Map
WV	West Virginia University Hospitals Inc	Morgantown26056	NCT06065748	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT06065748	Map
WI	University of WI - Carbone Cancer Center (Phase II only)	Madison53792	NCT05563220	Map
WI	University of Wisconsin	Madison53705	NCT05467891	Map
WI	UW Carbone Cancer Center	Madison53792	NCT05216432	Map
WI	Wisconsin Institute for Medical Research	Madison53792	NCT06625775	Map
WI	Aurora St Lukes Medical Center	Milwaukee53215	NCT06065748	Map

Ribociclib clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	not yet recruiting	unknown	available	Total
Early P1	1	1		1	1					4
P1	9	4		12	9	1		2		37
P1/P2	10	4		3	2	1		1		21
P2	14	10	1	11	2		2	3		43
P3	12	6		7	2	2	1			30
P4	2	1		1	1	1				6
N/A	6	1		6	1		1	2	1	18

Recruiting Ribociclib clinical trials (59)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06805812	PALMARES-2Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study	—	Breast Adenocarcinoma	3,500	May 2023
NCT07237256	NoLEEtaChemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib	P3	Breast Cancer	3,902	Dec 2025
NCT07492641	KANDELA-302BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease	P3	HR+/HER2- Breast Cancer	1,056	May 2026
NCT05843253	Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant	P2	High Grade Glioma	120	Aug 2024
NCT07340658	SIE-3A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer	P3	Advanced, Metastatic Breast Cancer	300	Aug 2026
NCT06757634	VIKTORIA-2Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)	P3	Breast Cancer	1,180	Jul 2025
NCT07174336	PIK3CAA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)	P3	Breast Neoplasms	920	Dec 2025
NCT06930859	ELEGANCENon-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia	—	Breast Cancer	2,766	Dec 2025
NCT05900206	ARIADNETrastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer	P2	Breast Cancer	370	Oct 2023
NCT05870579	[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer	P1	Breast Cancer	48	Nov 2023
NCT07085767	OPERA-02Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer	P3	Breast Cancer	1,000	Nov 2025
NCT06849947	Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer	P2	Breast Cancer Metastatic	272	Feb 2026
NCT02813135	ESMARTEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors	P1/P2	Pediatric Cancer	472	Aug 2016
NCT07400523	Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy	P3	Breast Cancer	446	Feb 2026
NCT07423611	RACEctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer	P2	Breast Cancer	388	Oct 2026
NCT06380751	EvoPAR-BR01Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer	P3	Advanced Breast Cancer	500	Aug 2024
NCT06953882	SELECTImpact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy	P2	HER2 Negative Breast Cancer	140	Jul 2025
NCT03424005	Morpheus-panBCA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	P1/P2	Metastatic Breast Cancer	792	Mar 2018
NCT05827081	Adjuvant WIDERPhase IIIb Study of Ribociclib + ET in Early Breast Cancer	P3	Early Breast Cancer	1,400	Feb 2024
NCT05768139	PIKALO-1First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors	P1/P2	Breast Cancer	880	Apr 2023
NCT06830720	CAROLEENA Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence	—	Breast Neoplasms	3,250	Feb 2025
NCT05996107	Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer	P1	Breast Cancer	30	Feb 2024
NCT07164976	Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer	P1/P2	Breast Cancer	86	Oct 2025
NCT07405801	A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer	P2	Breast Cancer	80	Apr 2026
NCT05867251	Study of AVZO-021 in Patients With Advanced Solid Tumors	P1/P2	Advanced Solid Tumor	430	Aug 2023
NCT06905301	IMPULSEImplementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice	—	Breast Cancer	240	Jan 2026
NCT05467891	RaPhLRRRibociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer	P2	Locoregional Recurrence	200	Sep 2022
NCT04862663	CAPItello-292Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)	P3	Locally Advanced (Inoperable) or Metastatic Breast Cancer	895	May 2021
NCT07391774	Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial	P3	Anatomic Stage II Breast Cancer AJCC v8	1,978	Feb 2027
NCT05203172	The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials	P4	Solid Tumors	46	Jul 2022
NCT05816655	Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer	P2	Metastatic Breast Cancer	202	May 2023
NCT04802759	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer	P1/P2	Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	316	Jun 2021
NCT06065748	A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)	P3	Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer	1,050	Dec 2023
NCT05563220	ELEVATEOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer	P1/P2	Breast Cancer	435	Jan 2023
NCT06797531	NISLEESARWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia	—	HR+/HER2- Early Breast Cancer	177	Aug 2025
NCT06625775	Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors	P1	Solid Tumor, Adult	392	Oct 2024
NCT07002177	A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC	P1/P2	Metastatic Breast Cancer	196	Jun 2025
NCT06726148	Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	P1/P2	Advanced HR+/HER2- Breast Cancer	280	Apr 2025
NCT06377852	CDKThe CDK4/6 Inhibitor Dosing Knowledge (CDK) Study	P3	Metastatic Breast Cancer	500	Oct 2024
NCT07195227	CADILLACEfficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer	P2	Hormon Receptor Positive Breast Cancer	150	Mar 2026
NCT05508906	Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer	P1	Metastatic Breast Cancer	190	Aug 2022
NCT05683418	A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer	P1	HR+/HER2-negative Breast Cancer	241	Feb 2023
NCT02925234	DRUPThe Drug Rediscovery Protocol (DRUP Trial)	P2	Cancer	1,550	Aug 2016
NCT06810492	The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment	N/A	Breast Cancer Stage III	40	Apr 2025
NCT04116541	MegaMOSTA Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.	P2	Malignant Solid Tumor	455	Jan 2020
NCT06481956	T-DM1 Combined With CDK4/6 Inhibitor Ribociclib	P2	HER2-positive Advanced Breast Cancer	40	Oct 2023
NCT07054190	A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer	P2	Breast Cancer	60	Sep 2025
NCT05238922	Study of INCB123667 in Subjects With Advanced Solid Tumors	P1	Solid Tumors	604	Jul 2022
NCT06188520	CYCAD-1A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors	P1/P2	ER+ HER2- Advanced Breast Cancer	564	Dec 2023
NCT06239467	PIKture-01First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer	P1	Advanced Cancer	200	Feb 2024
NCT06062498	Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer	P2	Estrogen-receptor-positive Breast Cancer	174	Sep 2023
NCT06409390	Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer	P2	Metastatic Breast Cancer	15	Aug 2024
NCT05216432	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer	P1	PIK3CA Mutation	930	Dec 2021
NCT06587789	Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer	—	Breast Cancer	286	Jan 2024
NCT05452213	CAPTOR-BCComprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients	P4	Breast Cancer	1,000	Oct 2022
NCT05766410	ORACLE-RIPAA Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC	P2	Breast Cancer	60	Sep 2022
NCT06959979	Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	Early P1	Medulloblastoma, Childhood	60	Nov 2024
NCT04315233	CHARGERibociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics	P1	Metastatic Breast Cancer	34	May 2021
NCT06656624	Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)	P2	Advanced Breast Cancer	190	Aug 2024

Ribociclib clinical trials by indication

Breast Cancer (48)

NCT	Acronym	Phase	Status	Title
NCT07237256	NoLEEta	P3	recruiting	Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
NCT06760637	FourLight-3	P3	active not recruiting	Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06757634	VIKTORIA-2	P3	recruiting	Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06930859	ELEGANCE	N/A	recruiting	Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
NCT05900206	ARIADNE	P2	recruiting	Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
NCT05870579	—	P1	recruiting	[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT07085767	OPERA-02	P3	recruiting	Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07400523	—	P3	recruiting	Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
+ 40 more, see All trials below.

Metastatic Breast Cancer (12)

NCT	Acronym	Phase	Status	Title
NCT03424005	Morpheus-panBC	P1/P2	recruiting	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT05161195	—	P4	active not recruiting	Roll-over Study to Allow Continued Access to Ribociclib
NCT05816655	—	P2	recruiting	Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
NCT07002177	—	P1/P2	recruiting	A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
NCT06377852	CDK	P3	recruiting	The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT05508906	—	P1	recruiting	Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT06409390	—	P2	recruiting	Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
NCT05207709	HARMONIA	P3	active not recruiting	Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
+ 4 more, see All trials below.

Advanced Breast Cancer (6)

NCT	Acronym	Phase	Status	Title
NCT06380751	EvoPAR-BR01	P3	recruiting	Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT07274709	—	N/A	completed	Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases
NCT06656624	—	P2	recruiting	Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
NCT06375707	—	P2	unknown	Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
NCT02422615	MONALEESA-3	P3	completed	Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
NCT02599363	LEE011	P1	completed	A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer

Breast Neoplasms (3)

NCT	Acronym	Phase	Status	Title
NCT07174336	PIK3CA	P3	recruiting	A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT06830720	CAROLEEN	N/A	recruiting	A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
NCT03283384	NEOLBC	P2	active not recruiting	Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.

Early Breast Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT05827081	Adjuvant WIDER	P3	recruiting	Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT03701334	NATALEE	P3	active not recruiting	A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT01919229	MONALEESA-1	P2	terminated	A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

Advanced, Metastatic Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07340658	SIE-3	P3	not yet recruiting	A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
NCT01958021	MONALEESA-2	P3	completed	Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 (2)

NCT	Acronym	Phase	Status	Title
NCT07391774	—	P3	recruiting	Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
NCT05319873	—	P1/P2	active not recruiting	Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Breast Cancer Metastatic (2)

NCT	Acronym	Phase	Status	Title
NCT06849947	—	P2	not yet recruiting	Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
NCT03555877	AMICA	P2	completed	Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

High Grade Glioma (2)

NCT	Acronym	Phase	Status	Title
NCT05843253	—	P2	recruiting	Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
NCT02607124	—	P1/P2	terminated	A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy

ER+ HER2- Advanced Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06188520	CYCAD-1	P1/P2	recruiting	A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT03616587	SERENA-1	P1	active not recruiting	Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Breast Cancer Stage IV (2)

NCT	Acronym	Phase	Status	Title
NCT05625087	SAFIR 03	P2	active not recruiting	Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
NCT04852081	—	N/A	unknown	Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

PIK3CA Mutation (2)

NCT	Acronym	Phase	Status	Title
NCT05216432	—	P1	recruiting	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT05759949	—	P1	completed	First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Neuroblastoma (2)

NCT	Acronym	Phase	Status	Title
NCT05429502	LEE011	P1	terminated	Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
NCT02780128	NEPENTHE	P1	terminated	Next Generation Personalized Neuroblastoma Therapy

Solid Tumors (2)

NCT	Acronym	Phase	Status	Title
NCT05203172	—	P4	recruiting	The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
NCT05238922	—	P1	recruiting	Study of INCB123667 in Subjects With Advanced Solid Tumors

Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT02925234	DRUP	P2	recruiting	The Drug Rediscovery Protocol (DRUP Trial)
NCT04801966	TAILOR	N/A	terminated	Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Glioblastoma Multiforme (2)

NCT	Acronym	Phase	Status	Title
NCT02933736	LEE011	Early P1	active not recruiting	Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
NCT03834740	LEE011	Early P1	completed	A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Advanced Metastatic Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT02278120	MONALEESA-7	P3	completed	Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
NCT03096847	—	P3	completed	Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

HR+/HER2- Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07492641	KANDELA-302	P3	recruiting	BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Hormon Receptor Positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07195227	CADILLAC	P2	recruiting	Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

HR+/HER2- Early Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06797531	NISLEESA	N/A	recruiting	RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

HER2 Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06953882	SELECT	P2	recruiting	Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Advanced HR+/HER2- Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06726148	—	P1/P2	recruiting	Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Breast Cancer Stage III (1)

NCT	Acronym	Phase	Status	Title
NCT06810492	—	N/A	not yet recruiting	The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

Medulloblastoma, Childhood (1)

NCT	Acronym	Phase	Status	Title
NCT06959979	—	Early P1	recruiting	Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

Solid Tumor, Adult (1)

NCT	Acronym	Phase	Status	Title
NCT06625775	—	P1	recruiting	Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

CYP3A4*22 (1)

NCT	Acronym	Phase	Status	Title
NCT05691400	—	P4	withdrawn	Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype

Advanced Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06239467	PIKture-01	P1	recruiting	First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06065748	—	P3	recruiting	A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

HER2-positive Advanced Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06481956	—	P2	enrolling by invitation	T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

Estrogen-receptor-positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06062498	—	P2	recruiting	Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Advanced Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT05867251	—	P1/P2	recruiting	Study of AVZO-021 in Patients With Advanced Solid Tumors

HER2 Negative Breast Cancer Not Immediately Operated (1)

NCT	Acronym	Phase	Status	Title
NCT05664893	CALHYS	P1/P2	withdrawn	Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)

Breast Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06805812	PALMARES-2	N/A	recruiting	Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

HR+/HER2-negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05683418	—	P1	recruiting	A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

KRAS G12C Mutant Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT05358249	KontRASt-03	P1/P2	active not recruiting	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Locoregional Recurrence (1)

NCT	Acronym	Phase	Status	Title
NCT05467891	RaPhLRR	P2	recruiting	Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

DILI (1)

NCT	Acronym	Phase	Status	Title
NCT06367335	ETIC	N/A	completed	Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer

Breast Cancer Stage II (1)

NCT	Acronym	Phase	Status	Title
NCT05296746	RIBOLARIS	P2	active not recruiting	Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Advanced Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT05252416	VELA	P1	terminated	(VELA) Study of BLU-222 in Advanced Solid Tumors

Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors (1)

NCT	Acronym	Phase	Status	Title
NCT05051956	—	N/A	unknown	Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

ER-Positive HER2-Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04964934	SERENA-6	P3	active not recruiting	Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04802759	—	P1/P2	recruiting	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Locally Advanced (Inoperable) or Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04862663	CAPItello-292	P3	recruiting	Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04417621	—	P2	active not recruiting	Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 (1)

NCT	Acronym	Phase	Status	Title
NCT04585724	—	P1	withdrawn	Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Head and Neck Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04213404	RISE-HN	P1	unknown	Ribociclib and Spartalizumab in R/M HNSCC

Malignant Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04116541	MegaMOST	P2	recruiting	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Non-small Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04000529	—	P1	terminated	Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Breast Cancer Female (1)

NCT	Acronym	Phase	Status	Title
NCT04055493	ADAPTcycle	P3	active not recruiting	Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

HER2-positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03913234	—	P1/P2	unknown	Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Anatomic Stage IV Breast Cancer AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT04256941	—	P2	terminated	Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Low Grade Serous Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03673124	—	P2	active not recruiting	Ribociclib and Letrozole Treatment in Ovarian Cancer

Acute Lymphoblastic Leukemia ALL (1)

NCT	Acronym	Phase	Status	Title
NCT03740334	—	P1	active not recruiting	Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Estrogen Receptor and/or Progesterone Receptor Positive (1)

NCT	Acronym	Phase	Status	Title
NCT03477396	—	P2	completed	Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Triple Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03090165	—	P1/P2	active not recruiting	Ribociclib and Bicalutamide in AR+ TNBC

Squamous Cell Carcinoma of the Head and Neck (1)

NCT	Acronym	Phase	Status	Title
NCT03179956	—	Early P1	terminated	Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Anaplastic Astrocytoma (1)

NCT	Acronym	Phase	Status	Title
NCT03434262	SJDAWN	P1	completed	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

EGFR-mutant Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03333343	—	P1	active not recruiting	Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

CNS Embryonal Tumor, Not Otherwise Specified (1)

NCT	Acronym	Phase	Status	Title
NCT03387020	—	P1	completed	Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

Advanced Malignant Solid Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT03237390	—	P1	completed	Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

Diffuse Intrinsic Pontine Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT03355794	DIPG	P1	completed	A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)

Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03294694	—	P1	terminated	Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Recurrent Endometrial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03008408	—	P2	active not recruiting	A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Soft Tissue Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT03114527	DDL	P2	active not recruiting	Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03056833	LEE-011	P1	completed	Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer

Advanced Soft Tissue Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT03009201	—	P1	completed	Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02974725	—	P1	terminated	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Pediatric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02813135	ESMART	P1/P2	recruiting	European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Liposarcomas, Dedifferentiated (1)

NCT	Acronym	Phase	Status	Title
NCT03096912	—	P2	unknown	A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

Estrogen Receptor Positive (1)

NCT	Acronym	Phase	Status	Title
NCT02657928	—	P2	completed	Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

Solid Tumors for Phase Ib (1)

NCT	Acronym	Phase	Status	Title
NCT02703571	—	P1	terminated	Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Liposarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT02571829	—	P2	unknown	A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

Glioblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT02345824	—	P1	unknown	Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma

Castration-Resistant Prostate Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02555189	—	P1/P2	terminated	Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Breast Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT02608216	—	P1	active not recruiting	[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

Prostate Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02494921	—	P1/P2	completed	LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Advanced Digestive System Neuroendocrine Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT02420691	—	P2	completed	Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02414724	—	P1	terminated	Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma

Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02292550	—	P1	completed	Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02035813	—	P2	completed	DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Ribociclib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
CAPTOR-BC	NCT05452213	P4	recruiting	Breast Cancer	1,000	—
Clinical and P	NCT07487129	P4	completed	Breast Cancer	206	—
LEANORA	NCT04657679	P4	terminated	Breast Cancer	21	—
NoLEEta	NCT07237256	P3	recruiting	Breast Cancer	3,902	—
FourLight-3	NCT06760637	P3	active not recruiting	Breast Cancer	1,035	—
KANDELA-302	NCT07492641	P3	recruiting	HR+/HER2- Breast Cancer	1,056	—
SIE-3	NCT07340658	P3	not yet recruiting	Advanced, Metastatic Breast Cancer	300	—
VIKTORIA-2	NCT06757634	P3	recruiting	Breast Cancer	1,180	—
PIK3CA	NCT07174336	P3	recruiting	Breast Neoplasms	920	—
OPERA-02	NCT07085767	P3	recruiting	Breast Cancer	1,000	—
EvoPAR-BR01	NCT06380751	P3	recruiting	Advanced Breast Cancer	500	—
Adjuvant WIDER	NCT05827081	P3	recruiting	Early Breast Cancer	1,400	—
NATALEE	NCT03701334	P3	active not recruiting	Early Breast Cancer	5,101	PMID 37275963
CAPItello-292	NCT04862663	P3	recruiting	Locally Advanced (Inoperable) or Metastatic Breast Cancer	895	—
CDK	NCT06377852	P3	recruiting	Metastatic Breast Cancer	500	—
SERENA-6	NCT04964934	P3	active not recruiting	ER-Positive HER2-Negative Breast Cancer	315	PMID 37070653
ADAPTcycle	NCT04055493	P3	active not recruiting	Breast Cancer Female	1,684	PMID 37695655
HARMONIA	NCT05207709	P3	active not recruiting	Metastatic Breast Cancer	456	PMID 37207300
DISCORDANT	NCT06585969	P3	withdrawn	Metastatic Breast Cancer	0	—
EarLEE-2	NCT03081234	P3	withdrawn	Breast Cancer	0	—
BioItaLEE	NCT03439046	P3	completed	Breast Cancer	287	—
MONALEESA-7	NCT02278120	P3	completed	Advanced Metastatic Breast Cancer	672	PMID 29804902
MONALEESA-2	NCT01958021	P3	completed	Advanced, Metastatic Breast Cancer	668	PMID 31305131
MONALEESA-3	NCT02422615	P3	completed	Advanced Breast Cancer	726	PMID 34102253
RIBBIT	NCT03462251	P3	completed	Breast Cancer	41	—
COMPLEEMENT-1	NCT02941926	P3	completed	Breast Cancer	3,246	PMID 36206609
ARIADNE	NCT05900206	P2	recruiting	Breast Cancer	370	PMID 40866060
RIBOLARIS	NCT05296746	P2	active not recruiting	Breast Cancer Stage II	1,100	—
RACE	NCT07423611	P2	not yet recruiting	Breast Cancer	388	—
SELECT	NCT06953882	P2	recruiting	HER2 Negative Breast Cancer	140	—
SAFIR 03	NCT05625087	P2	active not recruiting	Breast Cancer Stage IV	162	—
RaPhLRR	NCT05467891	P2	recruiting	Locoregional Recurrence	200	—
CADILLAC	NCT07195227	P2	recruiting	Hormon Receptor Positive Breast Cancer	150	—
DRUP	NCT02925234	P2	recruiting	Cancer	1,550	PMID 37424386
MegaMOST	NCT04116541	P2	recruiting	Malignant Solid Tumor	455	—
NEOLBC	NCT03283384	P2	active not recruiting	Breast Neoplasms	100	—
DDL	NCT03114527	P2	active not recruiting	Soft Tissue Sarcoma	48	—
FELINE	NCT02712723	P2	active not recruiting	Breast Cancer	121	—
LEADER	NCT03285412	P2	active not recruiting	Breast Cancer	120	—
ORACLE-RIPA	NCT05766410	P2	recruiting	Breast Cancer	60	—
FACILE	NCT03944434	P2	active not recruiting	Breast Cancer	116	PMID 29058175
AMALEE	NCT03822468	P2	completed	Breast Cancer	376	PMID 40996770
NEOLETRIB	NCT05163106	P2	completed	Breast Cancer	85	PMID 39073142
RIGHT Choice	NCT03839823	P2	completed	Breast Cancer	222	PMID 38771995
AMICA	NCT03555877	P2	completed	Breast Cancer Metastatic	56	PMID 37690320
EarLEE-1	NCT03078751	P2	completed	Breast Cancer	54	PMID 17513820
CORALLEEN	NCT03248427	P2	completed	Breast Cancer	106	PMID 36067616
MONALEESA-1	NCT01919229	P2	terminated	Early Breast Cancer	14	PMID 27336726

Terminated and withdrawn Ribociclib trials (23)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05691400withdrawnPhase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype
NCT05664893withdrawnStudy to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)
NCT06585969withdrawnA Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
NCT03081234withdrawnAdjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
NCT05252416terminated(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT05429502terminatedStudy of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
NCT05384119terminatedPhase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
NCT02974725terminatedA Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
NCT04000529terminatedPhase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
NCT04657679terminatedPharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts
NCT04256941terminatedAromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
NCT02555189terminatedEnzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
NCT04801966terminatedSafety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
NCT02780128terminatedNext Generation Personalized Neuroblastoma Therapy
NCT04585724withdrawnStereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
NCT03905343terminatedRibociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
NCT03294694terminatedRibociclib + PDR001 in Breast Cancer and Ovarian Cancer
NCT02703571terminatedStudy of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
NCT03050398terminatedA Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
NCT03179956terminatedImpact of Ribociclib on Head and Neck Squamous Cell Cancer
NCT02607124terminatedA Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
NCT02414724terminatedRibociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT01919229terminatedA Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

All Ribociclib trials (159)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06805812	PALMARES-2	Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study	—	recruiting	3,500	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	May 2023
NCT07237256	NoLEEta	Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib	P3	recruiting	3,902	UNICANCER	Dec 2025
NCT06760637	FourLight-3	Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease	P3	active not recruiting	1,035	Pfizer	Jan 2025
NCT07492641	KANDELA-302	BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease	P3	recruiting	1,056	BeOne Medicines	May 2026
NCT05843253		Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant	P2	recruiting	120	Nationwide Children's Hospital	Aug 2024
NCT07340658	SIE-3	A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer	P3	not yet recruiting	300	Rovi Pharmaceuticals Laboratories	Aug 2026
NCT06757634	VIKTORIA-2	Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)	P3	recruiting	1,180	Celcuity Inc	Jul 2025
NCT07174336	PIK3CA	A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)	P3	recruiting	920	Eli Lilly and Company	Dec 2025
NCT06930859	ELEGANCE	Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia	—	recruiting	2,766	Novartis Pharmaceuticals	Dec 2025
NCT05900206	ARIADNE	Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer	P2	recruiting	370	Karolinska University Hospital	Oct 2023
NCT05870579		[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer	P1	recruiting	48	Novartis Pharmaceuticals	Nov 2023
NCT07085767	OPERA-02	Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer	P3	recruiting	1,000	Olema Pharmaceuticals, Inc.	Nov 2025
NCT06849947		Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer	P2	not yet recruiting	272	Yeon Hee Park	Feb 2026
NCT05296746	RIBOLARIS	Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer	P2	active not recruiting	1,100	SOLTI Breast Cancer Research Group	May 2022
NCT02813135	ESMART	European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors	P1/P2	recruiting	472	Gustave Roussy, Cancer Campus, Grand Paris	Aug 2016
NCT07400523		Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy	P3	recruiting	446	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Feb 2026
NCT07423611	RACE	ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer	P2	not yet recruiting	388	Fudan University	Oct 2026
NCT06380751	EvoPAR-BR01	Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer	P3	recruiting	500	AstraZeneca	Aug 2024
NCT06953882	SELECT	Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy	P2	recruiting	140	Yale University	Jul 2025
NCT03424005	Morpheus-panBC	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	P1/P2	recruiting	792	Hoffmann-La Roche	Mar 2018
NCT05827081	Adjuvant WIDER	Phase IIIb Study of Ribociclib + ET in Early Breast Cancer	P3	recruiting	1,400	Novartis Pharmaceuticals	Feb 2024
NCT05161195		Roll-over Study to Allow Continued Access to Ribociclib	P4	active not recruiting	134	Novartis Pharmaceuticals	Jul 2022
NCT05768139	PIKALO-1	First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors	P1/P2	recruiting	880	Eli Lilly and Company	Apr 2023
NCT06830720	CAROLEEN	A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence	—	recruiting	3,250	Novartis Pharmaceuticals	Feb 2025
NCT05996107		Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer	P1	recruiting	30	University of Michigan Rogel Cancer Center	Feb 2024
NCT05625087	SAFIR 03	Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib	P2	active not recruiting	162	UNICANCER	Oct 2023
NCT03701334	NATALEE	A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer	P3	active not recruiting	5,101	Novartis Pharmaceuticals	Dec 2018
NCT07164976		Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer	P1/P2	recruiting	86	Nagoya City University	Oct 2025
NCT07405801		A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer	P2	recruiting	80	Hoffmann-La Roche	Apr 2026
NCT05867251		Study of AVZO-021 in Patients With Advanced Solid Tumors	P1/P2	recruiting	430	Avenzo Therapeutics, Inc.	Aug 2023
NCT06905301	IMPULSE	Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice	—	recruiting	240	Novartis Pharmaceuticals	Jan 2026
NCT05467891	RaPhLRR	Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer	P2	recruiting	200	Oana Danciu	Sep 2022
NCT04862663	CAPItello-292	Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)	P3	recruiting	895	AstraZeneca	May 2021
NCT07391774		Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial	P3	recruiting	1,978	National Cancer Institute (NCI)	Feb 2027
NCT05203172		The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials	P4	recruiting	46	Pfizer	Jul 2022
NCT05816655		Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer	P2	recruiting	202	Korea University Guro Hospital	May 2023
NCT04802759		A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer	P1/P2	recruiting	316	Hoffmann-La Roche	Jun 2021
NCT06065748		A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)	P3	recruiting	1,050	Hoffmann-La Roche	Dec 2023
NCT05563220	ELEVATE	Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer	P1/P2	recruiting	435	Stemline Therapeutics, Inc.	Jan 2023
NCT06797531	NISLEESA	RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia	—	recruiting	177	Novartis Pharmaceuticals	Aug 2025
NCT06625775		Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors	P1	recruiting	392	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	Oct 2024
NCT07002177		A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC	P1/P2	recruiting	196	Forward Pharmaceuticals Co., Ltd.	Jun 2025
NCT06726148		Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	P1/P2	recruiting	280	Novartis Pharmaceuticals	Apr 2025
NCT06377852	CDK	The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study	P3	recruiting	500	American Society of Clinical Oncology	Oct 2024
NCT04964934	SERENA-6	Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)	P3	active not recruiting	315	AstraZeneca	Jun 2021
NCT03008408		A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma	P2	active not recruiting	90	M.D. Anderson Cancer Center	Aug 2017
NCT05319873		Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer	P1/P2	active not recruiting	18	Jonsson Comprehensive Cancer Center	Apr 2022
NCT07195227	CADILLAC	Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer	P2	recruiting	150	MedSIR	Mar 2026
NCT05508906		Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer	P1	recruiting	190	Olema Pharmaceuticals, Inc.	Aug 2022
NCT05683418		A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer	P1	recruiting	241	Totus Medicines	Feb 2023
NCT02925234	DRUP	The Drug Rediscovery Protocol (DRUP Trial)	P2	recruiting	1,550	The Netherlands Cancer Institute	Aug 2016
NCT06810492		The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment	N/A	not yet recruiting	40	Hongmei Zheng, PhD	Apr 2025
NCT04116541	MegaMOST	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.	P2	recruiting	455	Centre Leon Berard	Jan 2020
NCT06481956		T-DM1 Combined With CDK4/6 Inhibitor Ribociclib	P2	enrolling by invitation	40	Zheng Yabing	Oct 2023
NCT07054190		A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer	P2	recruiting	60	Hoffmann-La Roche	Sep 2025
NCT05238922		Study of INCB123667 in Subjects With Advanced Solid Tumors	P1	recruiting	604	Incyte Corporation	Jul 2022
NCT03283384	NEOLBC	Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.	P2	active not recruiting	100	Borstkanker Onderzoek Groep	Jun 2019
NCT06188520	CYCAD-1	A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors	P1/P2	recruiting	564	AstraZeneca	Dec 2023
NCT06239467	PIKture-01	First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer	P1	recruiting	200	OnKure, Inc.	Feb 2024
NCT04055493	ADAPTcycle	Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC	P3	active not recruiting	1,684	West German Study Group	Jul 2019
NCT06062498		Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer	P2	recruiting	174	Northwestern University	Sep 2023
NCT03616587	SERENA-1	Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.	P1	active not recruiting	396	AstraZeneca	Oct 2018
NCT06409390		Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer	P2	recruiting	15	H. Lee Moffitt Cancer Center and Research Institute	Aug 2024
NCT05216432		First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer	P1	recruiting	930	Relay Therapeutics, Inc.	Dec 2021
NCT05691400		Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype	P4	withdrawn	0	University of Michigan Rogel Cancer Center	Mar 2024
NCT02933736	LEE011	Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients	Early P1	active not recruiting	48	Nader Sanai	Oct 2016
NCT05207709	HARMONIA	Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype	P3	active not recruiting	456	SOLTI Breast Cancer Research Group	Mar 2022
NCT04417621		Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma	P2	active not recruiting	134	Novartis Pharmaceuticals	Oct 2020
NCT06587789		Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer	—	recruiting	286	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jan 2024
NCT03673124		Ribociclib and Letrozole Treatment in Ovarian Cancer	P2	active not recruiting	51	Gynecologic Oncology Group	May 2019
NCT03114527	DDL	Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)	P2	active not recruiting	48	Fox Chase Cancer Center	Aug 2017
NCT02712723	FELINE	Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer	P2	active not recruiting	121	Qamar Khan	Feb 2016
NCT06495164		A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer	—	active not recruiting	1	Pfizer	Jun 2024
NCT05573555	TACTIVE-U	TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)	P1/P2	active not recruiting	20	Pfizer	Mar 2023
NCT02608216		[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer	P1	active not recruiting	20	University of Pennsylvania	Nov 2015
NCT05452213	CAPTOR-BC	Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients	P4	recruiting	1,000	Institut fuer Frauengesundheit	Oct 2022
NCT03090165		Ribociclib and Bicalutamide in AR+ TNBC	P1/P2	active not recruiting	37	Kari Wisinski	May 2018
NCT03285412	LEADER	CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	P2	active not recruiting	120	Massachusetts General Hospital	Dec 2017
NCT03333343		Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC	P1	active not recruiting	105	Novartis Pharmaceuticals	Jan 2018
NCT03740334		Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL	P1	active not recruiting	45	Dana-Farber Cancer Institute	Jan 2019
NCT05766410	ORACLE-RIPA	A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC	P2	recruiting	60	National Taiwan University Hospital	Sep 2022
NCT06959979		Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	Early P1	recruiting	60	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Nov 2024
NCT04315233	CHARGE	Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics	P1	recruiting	34	University of Utah	May 2021
NCT05358249	KontRASt-03	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	P1/P2	active not recruiting	74	Novartis Pharmaceuticals	Oct 2022
NCT05664893	CALHYS	Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)	P1/P2	withdrawn	0	Centre Antoine Lacassagne	Jun 2023
NCT06585969	DISCORDANT	A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer	P3	withdrawn	0	Danish Breast Cancer Cooperative Group	Jan 2026
NCT07274709		Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases	—	completed	2,495	Shirley Vichy Wang	Sep 2025
NCT06656624		Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)	P2	recruiting	190	The First Affiliated Hospital with Nanjing Medical University	Aug 2024
NCT06375707		Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	P2	unknown	144	The First Affiliated Hospital with Nanjing Medical University	Jan 2024
NCT07487129	Clinical and P	Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	P4	completed	206	Beni-Suef University	Aug 2024
NCT03944434	FACILE	FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer	P2	active not recruiting	116	Fondazione Sandro Pitigliani	Dec 2018
NCT03081234	EarLEE-2	Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer	P3	withdrawn	0	Novartis Pharmaceuticals	Mar 2018
NCT05252416	VELA	(VELA) Study of BLU-222 in Advanced Solid Tumors	P1	terminated	50	Blueprint Medicines Corporation	Apr 2022
NCT03671330		Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.	P2	completed	327	Novartis Pharmaceuticals	Aug 2018
NCT05759949		First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors	P1	completed	41	Relay Therapeutics, Inc.	Mar 2023
NCT06311383	RIBANNA	A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment	—	completed	2,610	Novartis Pharmaceuticals	Oct 2017
NCT05429502	LEE011	Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors	P1	terminated	12	Novartis Pharmaceuticals	Dec 2022
NCT04213404	RISE-HN	Ribociclib and Spartalizumab in R/M HNSCC	P1	unknown	13	National Taiwan University Hospital	Mar 2020
NCT02344472		Detect V / CHEVENDO (Chemo vs. Endo)	P3	active not recruiting	271	Prof. Wolfgang Janni	Sep 2015
NCT03822468	AMALEE	Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer	P2	completed	376	Novartis Pharmaceuticals	Jun 2019
NCT05163106	NEOLETRIB	Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole	P2	completed	85	University Hospital, Akershus	Dec 2022
NCT03956654	RibOB	A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer	—	completed	78	Universitaire Ziekenhuizen KU Leuven	Dec 2018
NCT03434262	SJDAWN	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	P1	completed	68	St. Jude Children's Research Hospital	Mar 2018
NCT05384119		Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer	P1	terminated	6	Tvardi Therapeutics, Incorporated	Jan 2023
NCT02974725		A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	P1	terminated	241	Novartis Pharmaceuticals	Feb 2017
NCT04000529		Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies	P1	terminated	122	Novartis Pharmaceuticals	Jul 2019
NCT02035813		DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).	P2	completed	116	Prof. Wolfgang Janni	Jan 2014
NCT03439046	BioItaLEE	Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant	P3	completed	287	Novartis Pharmaceuticals	Feb 2018
NCT04657679	LEANORA	Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts	P4	terminated	21	Georgetown University	May 2021
NCT03913234		Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients	P1/P2	unknown	95	Yonsei University	Jun 2019
NCT04256941		Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study	P2	terminated	4	M.D. Anderson Cancer Center	May 2019
NCT02555189		Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression	P1/P2	terminated	52	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Dec 2015
NCT03009201		Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery	P1	completed	16	OHSU Knight Cancer Institute	Mar 2017
NCT03477396		Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer	P2	completed	2	City of Hope Medical Center	Jun 2018
NCT03839823	RIGHT Choice	Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer	P2	completed	222	Novartis Pharmaceuticals	Feb 2019
NCT02278120	MONALEESA-7	Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer	P3	completed	672	Novartis Pharmaceuticals	Nov 2014
NCT01958021	MONALEESA-2	Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer	P3	completed	668	Novartis Pharmaceuticals	Dec 2013
NCT02422615	MONALEESA-3	Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.	P3	completed	726	Novartis Pharmaceuticals	Jun 2015
NCT06367335	ETIC	Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer	—	completed	128	University of Milano Bicocca	Jun 2022
NCT04801966	TAILOR	Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study	N/A	terminated	3	Peter MacCallum Cancer Centre, Australia	Sep 2021
NCT02754011	GEP14-LEECAP	Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative	P1	completed	18	UNICANCER	Feb 2017
NCT03462251	RIBBIT	Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line	P3	completed	41	iOMEDICO AG	May 2018
NCT02941926	COMPLEEMENT-1	Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC	P3	completed	3,246	Novartis Pharmaceuticals	Nov 2016
NCT02780128	NEPENTHE	Next Generation Personalized Neuroblastoma Therapy	P1	terminated	66	Yael P Mosse	Jul 2016
NCT03056833	LEE-011	Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer	P1	completed	35	Ronald Buckanovich	Jun 2017
NCT03355794	DIPG	A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)	P1	completed	19	Children's Hospital Medical Center, Cincinnati	Nov 2017
NCT03555877	AMICA	Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer	P2	completed	56	GBG Forschungs GmbH	Mar 2018
NCT02657343		An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.	P1/P2	completed	25	Dana-Farber Cancer Institute	Mar 2016
NCT03237390		Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors	P1	completed	43	Mayo Clinic	Jan 2018
NCT03834740	LEE011	A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection	Early P1	completed	27	St. Joseph's Hospital and Medical Center, Phoenix	Jan 2019
NCT05051956		Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?	—	unknown	140	Namik Kemal University	Oct 2021
NCT04852081		Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.	—	unknown	1,000	Blokhin's Russian Cancer Research Center	Jan 2021
NCT05569187		Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer	—	completed	76	Novartis Pharmaceuticals	Mar 2021
NCT02586675	LEE011	TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer	P1	completed	7	H. Lee Moffitt Cancer Center and Research Institute	Feb 2016
NCT04585724		Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases	P1	withdrawn	0	Emory University	Jun 2020
NCT05038631		Managed Access Programs for LEE011, Ribociclib	—	available	0	Novartis Pharmaceuticals	—
NCT02494921		LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC	P1/P2	completed	43	Rahul Aggarwal	Nov 2015
NCT03905343		Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC	P3	terminated	25	Swiss Cancer Institute	Jun 2019
NCT03294694		Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer	P1	terminated	33	Dana-Farber Cancer Institute	Nov 2017
NCT02657928		Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer	P2	completed	40	Mayo Clinic	Jul 2016
NCT05153135		Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors	—	completed	4,320	Novartis Pharmaceuticals	May 2020
NCT03096912		A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma	P2	unknown	30	Assaf-Harofeh Medical Center	Jul 2016
NCT01857193	RAD001	Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer	P1	completed	132	Novartis Pharmaceuticals	Sep 2013
NCT03387020		Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors	P1	completed	22	Pediatric Brain Tumor Consortium	Jan 2018
NCT03078751	EarLEE-1	Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer	P2	completed	54	Novartis Pharmaceuticals	Jun 2017
NCT02732119	TRINITI-1	Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.	P1/P2	completed	104	Novartis Pharmaceuticals	Jun 2016
NCT03096847		Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer	P3	completed	502	Novartis Pharmaceuticals	Oct 2016
NCT02345824		Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma	P1	unknown	3	University of Virginia	Mar 2016
NCT02703571		Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors	P1	terminated	95	Novartis Pharmaceuticals	Jun 2016
NCT03248427	CORALLEEN	Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.	P2	completed	106	SOLTI Breast Cancer Research Group	Jul 2017
NCT02420691		Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin	P2	completed	21	M.D. Anderson Cancer Center	Aug 2015
NCT02599363	LEE011	A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer	P1	completed	18	Abramson Cancer Center at Penn Medicine	Jan 2016
NCT03050398		A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib	P3	terminated	8	Novartis Pharmaceuticals	Jun 2017
NCT03179956		Impact of Ribociclib on Head and Neck Squamous Cell Cancer	Early P1	terminated	1	Fox Chase Cancer Center	Apr 2018
NCT02292550		Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.	P1	completed	27	Novartis Pharmaceuticals	May 2015
NCT02607124		A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy	P1/P2	terminated	11	Children's Hospital Medical Center, Cincinnati	Apr 2016
NCT02571829		A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma	P2	unknown	30	Hadassah Medical Organization	May 2016
NCT02414724		Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma	P1	terminated	10	Roswell Park Cancer Institute	May 2015
NCT01919229	MONALEESA-1	A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)	P2	terminated	14	Novartis Pharmaceuticals	Oct 2013

Ribociclib clinical trials: frequently asked questions

How many Ribociclib clinical trials are there?: 159 Ribociclib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 55 are actively recruiting participants. 41 are marked completed.
Are Ribociclib clinical trials recruiting in 2026?: Yes — 55 Ribociclib trials are actively recruiting in 2026, with 582 U.S. sites across 48 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Ribociclib being studied for?: Ribociclib is being studied for Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, HER2-negative Breast Cancer, Breast Neoplasms and 329 more. The trials are grouped by indication on this page.
What phase is Ribociclib in?: Ribociclib clinical trials span 6 Phase 4, 30 Phase 3, 43 Phase 2, 37 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Ribociclib clinical trials?: The lead sponsor across the most Ribociclib trials is Novartis Pharmaceuticals, with 93 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ribociclibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Ribociclib overview Ribociclib evidence & publications